InventisBio Co Ltd (688382)

Currency in CNY
25.87
-1.66(-6.03%)
Closed·
688382 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
25.6427.80
52 wk Range
12.3249.68
Key Statistics
Bid/Ask
25.87 / 25.88
Prev. Close
27.53
Open
27.58
Day's Range
25.64-27.8
52 wk Range
12.32-49.68
Volume
17.71M
Average Volume (3m)
14.38M
1-Year Change
91.3462%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
688382 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
39.63
Upside
+53.17%
Members' Sentiments
Bearish
Bullish
ProTips
Stock has taken a big hit over the last week

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

InventisBio Co Ltd Company Profile

InventisBio Co., Limited, a clinical stage biotech company, engages in the discovery and development of therapeutics for cancer and metabolic diseases in China. The company’s drug candidates for the oncology therapeutic area include BPI-D0316, which is in Phase III clinical trial for the non-small cell lung cancer (NSCLS) indications; Taragarestrant, which is in Phase III clinical trial for the treatment of estrogen receptor positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer; and Gesorexel, which in Phase II clinical trial to treat various cancers, such as non-small cell lung cancer and colorectal cancer with KRASG12C mutations. Its drug candidates for the metabolic therapeutic area is D-0120, a Phase II clinical trial product for hyperuricemia and gout indications; and D-2570, a oral selective inhibitor for the treatment of autoimmune diseases such as psoriasis. In addition, the company offers preclinical products, including YF 087 for MSI high cancers, and YF550 for chromosome instability cancers. InventisBio Co., Limited was founded in 2013 and is headquartered in Pudong, China.

Employees
185
Market
China

Compare 688382 to Peers and Sector

Metrics to compare
688382
Peers
Sector
Relationship
P/E Ratio
−128.7x−15.2x−0.6x
PEG Ratio
−1.92−0.040.00
Price/Book
9.0x4.6x2.6x
Price / LTM Sales
82.9x13.5x3.4x
Upside (Analyst Target)
53.2%41.7%42.5%
Fair Value Upside
Unlock−7.7%5.8%Unlock

Analyst Ratings

4 Buy
0 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 39.63
(+53.17% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Earnings

Latest Release
Oct 30, 2025
EPS / Forecast
-0.10 / --
Revenue / Forecast
12.00M / --
EPS Revisions
Last 90 days

688382 Income Statement

FAQ

What Is the InventisBio (688382) Stock Price Today?

The InventisBio stock price today is 25.87

What Stock Exchange Does InventisBio Trade On?

InventisBio is listed and trades on the Shanghai Stock Exchange stock exchange.

What Is the Stock Symbol for InventisBio?

The stock symbol for InventisBio is "688382."

What Is the InventisBio Market Cap?

As of today, InventisBio market cap is 15.92B.

What Is InventisBio's Earnings Per Share (TTM)?

The InventisBio EPS (TTM) is -0.20.

When Is the Next InventisBio Earnings Date?

InventisBio will release its next earnings report on Mar 28, 2026.

From a Technical Analysis Perspective, Is 688382 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has InventisBio Stock Split?

InventisBio has split 0 times.

How Many Employees Does InventisBio Have?

InventisBio has 185 employees.

What is the current trading status of InventisBio (688382)?

As of Jan 22, 2026, InventisBio (688382) is trading at a price of 25.87, with a previous close of 27.53. The stock has fluctuated within a day range of 25.64 to 27.80, while its 52-week range spans from 12.32 to 49.68.

What Is InventisBio (688382) Price Target According to Analysts?

The average 12-month price target for InventisBio is CNY39.63, with a high estimate of CNY49.25 and a low estimate of CNY30. 4 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +53.17% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.